scholarly journals Population pharmacokinetic−pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period

2014 ◽  
Vol 78 (5) ◽  
pp. 1102-1112 ◽  
Author(s):  
Min Dong ◽  
Tsuyoshi Fukuda ◽  
Shareen Cox ◽  
Marij T. de Vries ◽  
David K. Hooper ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Mycophenolic Acid ◽  
Population Pharmacokinetic ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Pharmacodynamic Modelling

scholarly journals Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach

Renal Failure ◽  
2015 ◽  
Vol 37 (4) ◽  
pp. 652-658 ◽  
Author(s):  
Radmila M. Veličković-Radovanović ◽  
Slobodan M. Janković ◽  
Jasmina R. Milovanović ◽  
Aleksandra K. Catić-Đorđević ◽  
Ana A. Spasić ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Mycophenolic Acid ◽  
Population Pharmacokinetic ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Pharmacokinetic Approach

scholarly journals Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update

Nephron ◽  
2021 ◽  
pp. 1-13
Author(s):  
Ana Elena Rodríguez-Rodríguez ◽  
Esteban Porrini ◽  
Mads Hornum ◽  
Javier Donate-Correa ◽  
Raúl Morales-Febles ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Renal Transplant ◽  
Cell Function ◽  
Cell Damage ◽  
Current Evidence ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Β Cell Function

Post-transplant diabetes mellitus (PTDM) is a frequent and relevant complication after renal transplantation: it affects 20–30% of renal transplant recipients and increases the risk for cardiovascular and infectious events. Thus, understanding pathogenesis of PTDM would help limiting its consequences. In this review, we analyse novel aspects of PTDM, based on studies of the last decade, such as the clinical evolution of PTDM, early and late, the reversibility rate, diagnostic criteria, risk factors, including pre-transplant metabolic syndrome and insulin resistance (IR) and the interaction between these factors and immunosuppressive medications. Also, we discuss novel pathogenic factors, in particular the role of β-cell function in an environment of IR and common pathways between pre-existing cell damage and tacrolimus-induced toxicity. The relevant role of prediabetes in the pathogenesis of PTDM and cardiovascular disease is also addressed. Finally, current evidence on PTDM treatment is discussed.

Sign in / Sign up

Export Citation Format

Share Document